Am J Perinatol 2021; 38(05): 414-420
DOI: 10.1055/s-0040-1717076
SMFM Fellowship Series Article

Cholestasis: A Prospective Study of Perinatal Outcomes and Time to Symptom Improvement

1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas
,
Denisse S. Holcomb
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas
,
Alexandria C. Kraus
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas
,
Charles E.L. Brown
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas
,
Donald D. McIntire
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas
,
David B. Nelson
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas
› Author Affiliations

Abstract

Objective Although intrahepatic cholestasis of pregnancy (ICP) remains poorly understood, there are several perinatal complications associated with this condition. This study aimed to examine perinatal outcomes of women with ICP, evaluate outcomes according to severity of disease, and monitor time to symptom improvement following diagnosis.

Study Design It involves a prospective, observational study of women with ICP at a single institution. Women with new-onset pruritus without rash were referred to a high-risk obstetrics clinic and evaluated with fasting total bile acids (TBA). Laboratory-confirmed ICP was defined as fasting TBA ≥10 µmol/L. Following diagnosis, a standardized protocol was utilized, including treatment with ursodeoxycholic acid (UDCA). Perinatal outcomes were compared amongst those with and without ICP, and to the general population. Women with ICP were further analyzed based on maximum TBA: 10 to 39, 40 to 99, and ≥100 µmol/L. A Kaplan-Meier survival curve was used to analyze time to symptom improvement.

Results A total of 404 patients were evaluated and 212 (52%) were diagnosed with ICP. The mean gestational age at diagnosis was 34.1 ± 3.3 weeks. When comparing those with ICP to those not confirmed, and to the general population, there were no differences in age, parity, mode of delivery, preeclampsia, or stillbirth (p > 0.05). Preterm birth was significantly associated with ICP (p < 0.01). This relationship was significant across increasing severity of TBA (p < 0.01) and persisted when examining rates of spontaneous preterm birth (p < 0.01). All women with fasting TBA ≥40 µmol/L delivered preterm due to premature rupture of membranes or spontaneous labor. Time to symptom improvement after diagnosis was over 2 weeks on average; however, this time increased with worsening severity of disease.

Conclusion Despite treatment with UDCA, women with ICP are at increased risk for spontaneous preterm birth, and this risk significantly increased with severity of disease. Although not significant, a trend exists between increasing time to symptom improvement and worsening severity of disease.

Key Points

  • Preterm birth is significantly increased in patients diagnosed with intrahepatic cholestasis of pregnancy.

  • The risk of preterm birth in women with ICP increases across increasing strata of disease.

  • Following initiation of treatment in patients with ICP, symptom improvement takes more than 2 weeks.

Note

Portions of this manuscript were presented at the Society for Maternal Fetal Medicine Annual Meeting on February 7, 2020 in Grapevine, TX (Poster presentation, Abstract #502).




Publication History

Received: 21 May 2020

Accepted: 24 August 2020

Article published online:
24 September 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Lin J, Gu W, Hou Y. Diagnosis and prognosis of early-onset intrahepatic cholestasis of pregnancy: a prospective study. J Matern Fetal Neonatal Med 2019; 32 (06) 997-1003
  • 2 Allen AM, Kim WR, Larson JJ. et al. The epidemiology of liver diseases unique to pregnancy in a US community: a population-based study. Clin Gastroenterol Hepatol 2016; 14 (02) 287-94.e1 , 2
  • 3 Marathe JA, Lim WH, Metz MP, Scheil W, Dekker GA, Hague WM. A retrospective cohort review of intrahepatic cholestasis of pregnancy in a South Australian population. Eur J Obstet Gynecol Reprod Biol 2017; 218: 33-38
  • 4 Rook M, Vargas J, Caughey A, Bacchetti P, Rosenthal P, Bull L. Fetal outcomes in pregnancies complicated by intrahepatic cholestasis of pregnancy in a Northern California cohort. PLoS One 2012; 7 (03) e28343
  • 5 Wikström Shemer E, Marschall HU, Ludvigsson JF, Stephansson O. Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. BJOG 2013; 120 (06) 717-723
  • 6 Williams Obstetrics, 25e | AccessMedicine | McGraw-Hill Medical. 2019 . Accessed November 18, 2019 at: https://accessmedicine.mhmedical.com/book.aspx?bookid=1918
  • 7 Lee RH, Goodwin TM, Greenspoon J, Incerpi M. The prevalence of intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles population. J Perinatol 2006; 26 (09) 527-532
  • 8 Kremer AE, Bolier R, Dixon PH. et al. Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. J Hepatol 2015; 62 (04) 897-904
  • 9 Abu-Hayyeh S, Ovadia C, Lieu T. et al. Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology 2016; 63 (04) 1287-1298
  • 10 Egan N, Bartels A, Khashan AS. et al. Reference standard for serum bile acids in pregnancy. BJOG 2012; 119 (04) 493-498
  • 11 Glantz A, Marschall H-U, Mattsson L-A. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology 2004; 40 (02) 467-474
  • 12 Kenyon AP, Piercy CN, Girling J, Williamson C, Tribe RM, Shennan AH. Obstetric cholestasis, outcome with active management: a series of 70 cases. BJOG 2002; 109 (03) 282-288
  • 13 Williamson C, Hems LM, Goulis DG. et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG 2004; 111 (07) 676-681
  • 14 Zecca E, De Luca D, Marras M, Caruso A, Bernardini T, Romagnoli C. Intrahepatic cholestasis of pregnancy and neonatal respiratory distress syndrome. Pediatrics 2006; 117 (05) 1669-1672
  • 15 Glantz A, Marschall H-U, Lammert F, Mattsson L-A. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005; 42 (06) 1399-1405
  • 16 Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology 2014; 59 (04) 1482-1491
  • 17 Kawakita T, Parikh LI, Ramsey PS. et al. Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol 2015; 213 (04) 570.e1-570.e8
  • 18 Ovadia C, Seed PT, Sklavounos A. et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet 2019; 393 (10174): 899-909
  • 19 Bacq Y, Sentilhes L, Reyes HB. et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 2012; 143 (06) 1492-1501
  • 20 Gurung V, Middleton P, Milan SJ, Hague W, Thornton JG. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst Rev 2013; (06) CD000493
  • 21 Chappell LC, Bell JL, Smith A. PITCHES study group. et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet 2019; 394 (10201): 849-860
  • 22 Bull LN, Hu D, Shah S. et al. Intrahepatic cholestasis of pregnancy (ICP) in U.S. Latinas and Chileans: clinical features, ancestry analysis, and admixture mapping. PLoS One 2015; 10 (06) e0131211
  • 23 Castaño G, Burgueño A, Fernández Gianotti T, Pirola CJ, Sookoian S. The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy. Aliment Pharmacol Ther 2010; 31 (05) 583-592
  • 24 Sookoian S, Castaño G, Burgueño A, Gianotti TF, Pirola CJ. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol 2008; 48 (01) 125-132
  • 25 Dixon PH, Sambrotta M, Chambers J. et al. An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Sci Rep 2017; 7 (01) 11823
  • 26 Reichert MC, Lammert F. ABCB4 gene aberrations in human liver disease: an evolving spectrum. Semin Liver Dis 2018; 38 (04) 299-307
  • 27 Nelson B, Morrison S, Joseph H. et al. Travel volume to the United States from Countries and U.S. Territories with local Zika virus transmission. PLoS Curr 2016;8:pii:ecurrents.outbreaks.ac6d0f8c9c35e88825c1a1147697531c